Phaseline

Targets › ADAM9

ADAM9 (Disintegrin and metalloproteinase domain-containing protein 9): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Nov 2026.

Metalloprotease that cleaves and releases a number of molecules with important roles in tumorigenesis and angiogenesis, such as TEK, KDR, EPHB4, CD40, VCAM1 and CDH5. May mediate cell-cell, cell-matrix interactions and regulate the motility of cells via interactions with integrins..; FUNCTION: [Isoform 2]: May act as alpha-secretase for amyloid precursor protein (APP). (UniProt, Q13443)

Open in Phaseline: the race on ADAM9, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
MacroGenicsMGC028
anti-ADAM9 antibody-drug conjugate
ADAM9Phase 1Advanced Solid TumorsNov 2026

Conditions

Advanced Solid Tumors (1)

Modalities

protein or peptide (1)

Companies

MacroGenics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.